Lisinopril, Hydrochlorothiazide | Iruzide tablets 20 mg + 12.5 mg, 30 pcs.

release form

tablets



packaging 30 pcs

Indications

Arterial hypertension (in patients who are shown combination therapy).

Contraindications

hypersensitivity to the drug, other ACE inhibitors, and sulfanilamide derivatives

anuria

severe renal failure (Cl creatinine <30 ml / min)

angioedema (including the use of using high-flow membranes

hypercalcemia

hyponatremia

porphyria

precoma

hepatic coma

severe diabetes mellitus

age up to 18 years (efficacy and safety have not been established).

Caution: aortic stenosis / hypertrophic cardiomyopathy bilateral renal artery stenosis of a single kidney artery stenosis with progressive azotemia state after renal transplantation renal failure (creatinine Cl> 30 ml / min) primary hyperaldosteronism hypotension hypoplasia of bone marrow hyponatremia patients at increased risk low-salt or salt-free diet) hypovolemic conditions (including diarrhea, vomiting) connective tissue diseases (systemic I have lupus erythematosus, scleroderma) diabetes mellitus, gout, hyperuricemia, oppression of bone marrow hematopoiesis, hyperkalemia, ischemic heart disease, cerebrovascular disease (including cerebrovascular insufficiency), severe chronic heart failure, liver failure, old age.

Use during pregnancy and lactation

The use of lisinopril during pregnancy is contraindicated.

When pregnancy is established, Iruzid should be discontinued as soon as possible. Reception of inhibitors in the II and III trimester of pregnancy has an adverse effect on the fetus (a pronounced decrease in blood pressure, renal failure, hyperkalemia, skull hypoplasia, intrauterine death are possible).

There is no data on the adverse effects of the drug on the fetus if used during the first trimester. It is recommended to monitor newborns and infants who underwent intrauterine exposure to ACE inhibitors to timely detect a pronounced decrease in blood pressure, oliguria, hyperkalemia.

Breastfeeding should be discontinued for the period of treatment with Iruzide.

Composition

1 tablet contains:

Active ingredients:

lisinopril,

hydrochlorothiazide

Excipients:

dibasic calcium phosphate,

mannitol,

cornstarch, corn starch, corn starch

iron oxide yellow,

purified water.

Dosage and administration of

In case of essential arterial hypertension, the drug is prescribed orally 1 tablet once a day.

If necessary, the dose can be increased to 2 tablets 1 time per day.

Dose for renal failure

In patients with Cl creatinine from 30 to 80 ml / min, the drug can be used only after selecting a dose of the individual components of the drug. The recommended initial dose of lisinopril in uncomplicated renal failure is 5–10 mg.

Previous diuretic therapy

Symptomatic hypotension may occur after taking the initial dose of Iruzid®. Such cases are more common in patients with loss of fluid and electrolytes due to previous treatment with diuretics. Therefore, it is necessary to stop taking diuretics 2-3 days before the start of treatment with Iruzide

Side effects of

From the CCC side: marked decrease in blood pressure, chest pain rarely - orthostatic hypotension, tachycardia, bradycardia, onset of symptoms of heart failure, violation of AV conduction, myocardial infarction.

From the digestive tract: nausea, vomiting, abdominal pain, dry mouth, diarrhea, dyspepsia, anorexia, taste change, pancreatitis, hepatitis (hepatocellular and cholestatic), jaundice.

From the skin: urticaria, increased sweating, photosensitivity, skin itching, hair loss.

From the side of the nervous system: lability of mood, impaired concentration of attention, paresthesia, increased fatigue, drowsiness, convulsive twitching of the muscles of the limbs and lips rarely - asthenic syndrome, confusion.

From the respiratory system: dyspnea, bronchospasm, apnea.

From the hemopoietic system: leukopenia, thrombocytopenia, neutropenia, agranulocytosis, anemia (decreased hemoglobin, hematocrit, erythrocytopenia).

Allergic reactions: angioedema of the face, limbs, lips, tongue, epiglottis and / or larynx, skin rashes, itching, fever, vasculitis, positive reactions to antinuclear antibodies, increased ESR, eosinophilia.

From the genitourinary system: uremia, oliguria / anuria, impaired renal function, acute renal failure, decreased potency.

Laboratory indicators: hyperkalemia and / or hypokalemia, hyponatremia, hypomagnesemia, hypochloraemia, hypercalcemia, hyperuricemia, hyperglycemia, increased levels of urea and creatinine in blood plasma, hyperbilirubinemia, hypercholesterolemia, hypertemia, high blood pressure a history of kidney disease, diabetes mellitus and renovascular hypertension.

Other: dry cough, arthralgia, arthritis, myalgia, fever, impaired fetal development, exacerbation of gout.

Drug Interaction

When used concurrently with potassium-sparing diuretics (spironolactone, triamterene, amiloride), potassium, potassium-containing salt substitutes, the risk of developing hyperkalemia increases. Therefore, they can be jointly prescribed only on the basis of the individual decision of the attending physician with regular monitoring of serum potassium and renal function.

When used with vasodilators, barbiturates, phenothiazines, tricyclic antidepressants, ethanol - enhances antihypertensive effects.

When used with NSAIDs (indomethacin, etc.), estrogens reduce the antihypertensive effect of lisinopril.

With simultaneous use with lithium - slows down the elimination of lithium from the body (increased cardiotoxic and neurotoxic effects of lithium).

With simultaneous use with antacids and cholestyramine, there is a reduction in intestinal absorption.

The drug increases the neurotoxicity of salicylates, weakens the action of oral hypoglycemic drugs, norepinephrine, epinephrine and antipagotric drugs, enhances the effects (including side) of cardiac glycosides, the action of peripheral muscle relaxants, reduces excretion.

Reduces the effect of oral contraceptives. Ethanol enhances the antihypertensive effect of the drug. The concomitant use of methyldopa increases the risk of hemolysis.

Overdose

Symptoms: severe BP, dry mouth, drowsiness, urinary retention, constipation, anxiety, increased irritability.

Treatment: symptomatic therapy, fluid injection, blood pressure control, therapy, aimed at correction of dehydration and disturbances of water-salt balance. Control of urea, creatinine and electrolytes in serum, as well as diuresis.

Storage conditions

In the dark place at a temperature of no higher than 25 РC.

Shelf suitability

3 Year

dosage form

dosage form

tablets